Eric Cua
Overview
Explore the profile of Eric Cua including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
47
Citations
1422
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chawki S, Leturque N, Minier M, Gabassi A, Foubert V, Charreau I, et al.
Open Forum Infect Dis
. 2024 Aug;
11(8):ofae400.
PMID: 39100527
Study Part Of The Anrs-ipergay Clinical Trial: ClinicalTrials.gov number, NCT01473472.
2.
Giavina-Bianchi P, Cua E, Risso K, Mondain V, Vissian A, Joie C, et al.
J Allergy Clin Immunol Glob
. 2023 Oct;
2(4):100140.
PMID: 37781656
Background: ABX464 (obefazimod) is a small molecule that upregulates a single microRNA (miR-124) in immune cells and reduces the production of various inflammatory cytokines and chemokines. Objective: We assessed the...
3.
Chaix M, Leturque N, Gabassi A, Charreau I, Minier M, Pialoux G, et al.
J Clin Virol
. 2023 Jan;
160:105380.
PMID: 36638749
Background: Men who have sex with men (MSM) have an increased risk of infection by pathogens transmitted by the oro-fecal route. Here, we investigated the seroprevalence and incidence of hepatitis...
4.
Lions C, Laroche H, Mora M, Pialoux G, Cotte L, Cua E, et al.
HIV Med
. 2022 Aug;
24(2):191-201.
PMID: 35943165
Objectives: Our objective was to identify missed opportunities for the use of pre-exposure prophylaxis (PrEP) in people with recently acquired HIV, factors associated with PrEP knowledge, and reasons for not...
5.
Mariaggi A, Bauer R, Charre C, Gardiennet E, Meiffredy V, Ajana F, et al.
J Antimicrob Chemother
. 2022 Feb;
77(3):735-739.
PMID: 35195692
Background: Dolutegravir is a widespread integrase strand-transfer inhibitor (INSTI) recommended for treatment of primary HIV infection (PHI). PHI is a high-risk stage for sexual transmission because of the high viral...
6.
Zeggagh J, Bauer R, Delaugerre C, Carette D, Fressard L, Charreau I, et al.
AIDS
. 2022 Feb;
36(8):1129-1134.
PMID: 35142708
Objective: High rates of sexually transmitted infections (STIs) have been reported among pre-exposure prophylaxis (PrEP) users. We wished to assess the incidence and risk factors for recurrent STIs. Design: The...
7.
Kumar G, Cottalorda-Dufayard J, Garraffo R, De Salvador-Guillouet F, Cua E, Roger P
Cells
. 2022 Jan;
11(2).
PMID: 35053324
Raltegravir (RLT) prevents the integration of HIV DNA in the nucleus, but published studies remain controversial, suggesting that it does not decrease proviral DNA. However, there are only a few...
8.
Hall N, Allavena C, Katlama C, Jobert A, Molina J, Cua E, et al.
AIDS Res Ther
. 2022 Jan;
19(1):4.
PMID: 35033092
Background: Raltegravir (RAL) has favorable tolerability and safety profile, with few and manageable drug interactions. The use of RAL 1200 mg once daily (qd) for first-line therapy is well established....
9.
Gras J, Pillet M, Antoni G, Cua E, Charreau I, Raffi F, et al.
Sex Transm Infect
. 2021 Oct;
98(5):383-386.
PMID: 34663696
Objectives: We aimed to assess among men who have sex with men (MSM) risk factors for HIV infection, to identify those who require urgent pre-exposure prophylaxis (PrEP) prescription. Methods: All...
10.
Goldwirt L, Bauer R, Liegeon G, Charreau I, Delaugerre C, Cotte L, et al.
J Antimicrob Chemother
. 2021 Jul;
76(10):2675-2680.
PMID: 34278433
Background: Tenofovir diphosphate (TFV-DP) concentration in dried blood spots (DBSs) is a reliable pharmacokinetics biomarker of adherence to tenofovir disoproxil fumarate (TDF). We aimed to use DBSs to estimate pill...